X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs IPCA LABS - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS IPCA LABS NOVARTIS/
IPCA LABS
 
P/E (TTM) x 360.4 42.1 856.2% View Chart
P/BV x 17.7 3.2 549.7% View Chart
Dividend Yield % 1.6 0.2 1,021.6%  

Financials

 NOVARTIS   IPCA LABS
EQUITY SHARE DATA
    NOVARTIS
Mar-16
IPCA LABS
Mar-17
NOVARTIS/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs982643 152.7%   
Low Rs556503 110.6%   
Sales per share (Unadj.) Rs252.9254.4 99.4%  
Earnings per share (Unadj.) Rs62.116.1 386.7%  
Cash flow per share (Unadj.) Rs63.329.8 212.6%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.30.2 744.9%  
Book value per share (Unadj.) Rs363.6194.6 186.9%  
Shares outstanding (eoy) m31.96126.20 25.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.02.3 135.0%   
Avg P/E ratio x12.435.7 34.7%  
P/CF ratio (eoy) x12.219.2 63.2%  
Price / Book Value ratio x2.12.9 71.8%  
Dividend payout %16.16.2 258.6%   
Avg Mkt Cap Rs m24,58072,300 34.0%   
No. of employees `0000.813.3 5.7%   
Total wages/salary Rs m1,8016,960 25.9%   
Avg. sales/employee Rs Th10,748.92,413.5 445.4%   
Avg. wages/employee Rs Th2,395.2523.2 457.8%   
Avg. net profit/employee Rs Th2,641.1152.4 1,732.5%   
INCOME DATA
Net Sales Rs m8,08332,106 25.2%  
Other income Rs m829226 367.5%   
Total revenues Rs m8,91332,332 27.6%   
Gross profit Rs m2344,448 5.3%  
Depreciation Rs m371,730 2.1%   
Interest Rs m2241 0.7%   
Profit before tax Rs m1,0252,703 37.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m752675 111.4%   
Profit after tax Rs m1,9862,028 97.9%  
Gross profit margin %2.913.9 20.9%  
Effective tax rate %73.425.0 293.7%   
Net profit margin %24.66.3 389.0%  
BALANCE SHEET DATA
Current assets Rs m12,67817,340 73.1%   
Current liabilities Rs m2,4339,559 25.5%   
Net working cap to sales %126.724.2 523.0%  
Current ratio x5.21.8 287.3%  
Inventory Days Days33100 32.6%  
Debtors Days Days2257 39.5%  
Net fixed assets Rs m6920,779 0.3%   
Share capital Rs m160252 63.3%   
"Free" reserves Rs m11,46024,499 46.8%   
Net worth Rs m11,62124,553 47.3%   
Long term debt Rs m03,517 0.0%   
Total assets Rs m14,40039,595 36.4%  
Interest coverage x570.512.2 4,666.3%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.8 69.2%   
Return on assets %13.85.7 240.9%  
Return on equity %17.18.3 206.9%  
Return on capital %23.610.5 224.8%  
Exports to sales %0.748.6 1.5%   
Imports to sales %18.614.2 130.6%   
Exports (fob) Rs m6015,617 0.4%   
Imports (cif) Rs m1,5034,571 32.9%   
Fx inflow Rs m18615,617 1.2%   
Fx outflow Rs m1,8215,828 31.2%   
Net fx Rs m-1,6359,790 -16.7%   
CASH FLOW
From Operations Rs m2,5312,764 91.6%  
From Investments Rs m-8,270-1,432 577.6%  
From Financial Activity Rs m-386-1,591 24.2%  
Net Cashflow Rs m-6,125-259 2,366.5%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.4 17.5%  
FIIs % 1.6 25.3 6.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.4 123.6%  
Shareholders   41,647 36,892 112.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 19, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS